Ammosamides as anticancer agents
View Patent ↗A compound having the general the general structure I is provided: (Formula I), wherein Z is a substituent selected from a group consisting of S and O; X is a substituent selected from a group consisting of Cl, Br, I, OH and NH2; each of R 1 and R 2 is a substituent independently selected from a group consisting of H, a linear, cyclic or branched, substituted or unsubstituted C 1 -C 6 alkyl, a substituted or unsubstituted aryl, and a substituted or unsubstituted heteroaryl; and each of Y and Y 1 is a substituent independently selected from a group consisting of H and C(O)—C 6 H 4 —Br.
1. An isolated compound having the general structure I:
wherein:
Z is a substituent selected from a group consisting of S and O;
X is a substituent selected from a group consisting of Cl, Br, I;
each of R 1 and R 2 is a substituent independently selected from a group consisting of H; and
each of Y and Y 1 is a substituent independently selected from a group consisting of H.
2. The compound of claim 1 , wherein each of R 1 and R 2 is H.
3. The compound of claim 1 , wherein Z is S and X is Cl.
4. An isolated compound selected from a group consisting of compounds IA and IB:
5. A compound selected from the group consisting of compounds IC, ID and IE:
6. A pharmaceutical composition, comprising an effective amount of a compound of claim 1 or 4 or 5 , and a pharmaceutically acceptable carrier.
7. A method for inhibiting proliferation of mammalian cells, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 4 or 5 wherein the cells are colon, cervical or prostate cancer cells.
8. The method of claim 7 , wherein the proliferation is indicative of colon, cervical or prostate cancer.
9. A method for treating a mammalian cell proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 4 or 5 , wherein the disorder is cancer of the colon, cervix or prostate.
10. The method of claim 9 , wherein the proliferative disorder is colon cancer.
11. A method for producing a compound of claim 1 or 4 , comprising:
a) cultivating a culture of actinomycete strain CNR698-307 or CNR689-291; and
b) isolating compound I from the culture.
12. The method of claim 11 , wherein the compound is selected from a group consisting of compounds IA and IB:
13. An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treatment of a cell proliferative disorder and wherein said pharmaceutical composition comprises at least one compound of claim 1 or 4 or 5 .
14. A method for treating colon, cervical or prostate cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 4 or 5 .